文献速递炎症性肠病

IL-23p19拮抗剂与乌司奴单抗治疗克罗恩病的比较:随机对照试验的Meta分析

IL-23p19 Antagonists vs Ustekinumab for Treatment of Crohn's Disease: A Meta-Analysis of Randomized Controlled Trials.
PubMed 文献 · Am J Gastroenterol · 2025-03-12

该研究系统检索截至2024年8月17日的随机对照试验,纳入5项头对头RCT(n=2,506),比较IL-23p19拮抗剂与乌司奴单抗治疗中重度克罗恩病。Meta分析显示,IL-23p19拮抗剂在既往生物制剂暴露患者中可能更有效且更安全,但在生物制剂初治患者中未显示优势。

要点

  • IL-23p19拮抗剂在既往生物制剂暴露患者中临床缓解(RR 1.31)和内镜缓解(RR 1.61)优于乌司奴单抗。
  • 生物制剂初治患者中两组临床缓解(RR 0.99)和内镜缓解(RR 1.16)无显著差异。
  • IL-23p19拮抗剂严重不良事件风险可能低于乌司奴单抗(RR 0.79)。

核心结论

  • 在既往生物制剂暴露的中重度克罗恩病患者中,IL-23p19拮抗剂可能比乌司奴单抗更有效且更安全,但在生物制剂初治患者中未显示优势。

研究设计与样本

  • 系统综述与Meta分析,纳入5项头对头随机对照试验(采用treat-through设计,n=2,506),其中1项仅纳入既往肿瘤坏死因子拮抗剂暴露患者。
  • 检索截至2024年8月17日,纳入比较IL-23p19拮抗剂与乌司奴单抗治疗成人中重度克罗恩病的2期和3期随机对照试验。

主要发现

  • 总体分析:IL-23p19抑制剂相比乌司奴单抗可能更易达到临床缓解(RR 1.18,95%CI 1.02-1.36,低确定性证据)和内镜缓解(RR 1.53,95%CI 1.07-2.20)。
  • 亚组分析:既往生物制剂暴露患者中,IL-23p19拮抗剂临床缓解(RR 1.31,95%CI 1.16-1.48)和内镜缓解(RR 1.61,95%CI 1.27-2.05)优于乌司奴单抗(中至高质量证据)。
  • 亚组分析:生物制剂初治患者中,临床缓解(RR 0.99,95%CI 0.90-1.08)和内镜缓解(RR 1.16,95%CI 0.82-1.65)无显著差异。
  • IL-23p19拮抗剂相比乌司奴单抗可能降低严重不良事件风险(RR 0.79,95%CI 0.61-1.02)。

临床怎么用

  • 作者认为,在既往生物制剂暴露的中重度克罗恩病患者中,IL-23p19拮抗剂可能比乌司奴单抗更有效且更安全,但在生物制剂初治患者中未显示优势。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) comparing interleukin (IL)-23p19 antagonists with ustekinumab, stratified by prior biologic exposure, in patients with moderate-to-severe Crohn's disease (CD). METHODS: Through a systematic review through August 17, 2024, we identified phase 2 and 3 RCTs comparing IL-23p19 antagonists vs ustekinumab in adults with moderate-to-severe CD. The primary outcome was achieving clinical remission at ∼1 year, and secondary outcomes were achieving endoscopic remission and serious adverse events. We performed subgroup analyses based on prior exposure to biologic therapy, primarily tumor necrosis factor antagonists. Certainty of evidence was appraised using the Grading of Recommendations Assessment, Development, and Evaluation approach. RESULTS: We included 5 head-to-head RCTs with a treat-through design (n = 2,506), of which 1 was conducted exclusively in patients with prior tumor necrosis factor antagonist exposure. On meta-analysis, patients treated with IL-23p19 inhibitors may be more likely to achieve clinical remission (relative risk [RR], 1.18 95% confidence interval [CI] 1.02-1.36) (low certainty of evidence) and endoscopic remission (RR 1.53, 95% CI 1.07-2.20) compared with ustekinumab. On subgroup analysis, IL-23p19 antagonists are probably more efficacious than ustekinumab in patients with prior biologic exposure (clinical remission: RR 1.31, 95% CI 1.16-1.48; endoscopic remission: RR 1.61, 95% CI 1.27-2.05) (moderate to high certainty), but not in biologic-naive patients (clinical remission: RR 0.99, 95% CI 0.90-1.08; endoscopic remission: RR 1.16, 95% CI 0.82-1.65). IL-23p19 antagonists may be associated with a lower risk of serious adverse events as compared with ustekinumab (RR 0.79, 95% CI 0.61-1.02). DISCUSSION: IL-23p19 antagonists are probably more efficacious and safer than ustekinumab in patients with moderate-to-severe CD in patients with prior biologic exposure, but not in biologic-naive patients.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Dziegielewski C, Yuan Y, Ma C, et al. IL-23p19 Antagonists vs Ustekinumab for Treatment of Crohn's Disease: A Meta-Analysis of Randomized Controlled Trials. Am J Gastroenterol. 2025. PMID: 40071763. doi:10.14309/ajg.0000000000003406

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。